Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Head and Neck Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Colonic Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Cyclophosphamide 77Paclitaxel 48Trastuzumab 40Tamoxifen 39Doxorubicin 37Docetaxel 35Radiotherapy 32Fluorouracil 26Chemotherapy, Adjuvant 26Taxes 23Epirubicin 22Carboplatin 22Filgrastim 21Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 19Neoadjuvant Therapy 18aldesleukin 16Peripheral Blood Stem Cell Transplantation 16Bevacizumab 13Lapatinib 12CMF regimen 12Anastrozole 12exemestane 11Goserelin 11Capecitabine 11Biopsy 11veliparib 10sargramostim 10fludarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms × bintrafusp alfa protein, human × Clear all
NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡